Further on this subject, DMX would make a great case study for a conference workshop.
A company with a clinically proven product, efficacy and safety, targeting OA patients. OA is chronic, no cures available, some on drugs for years. Documented cases of hositalizations and even deaths due to competitor's NSAID products. Pennsaid meandering in the HC queue for years. Completed Phase I, II, III, IV, III, then way past 300th day for a reply.
Oh, did I mention DMX would make a great case study at the conference workshop.
[EDIT]
The DMX balancing act. I feel DMX's low key, don't rock the boat stance with HC did not help their cause. Having said that, I do understand unnecessary media hype would hurt their cause with HC (and FDA).
Just 'filler' thoughts. |
